KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Invested Capital (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Invested Capital for 15 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 0.89% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 0.89% year-over-year, with the annual reading at $1.1 billion for FY2025, 0.89% up from the prior year.
  • Invested Capital for Q4 2025 was $1.1 billion at Supernus Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • The five-year high for Invested Capital was $1.3 billion in Q3 2022, with the low at $786.0 million in Q1 2021.
  • Average Invested Capital over 5 years is $1.0 billion, with a median of $997.6 million recorded in 2023.
  • The sharpest move saw Invested Capital skyrocketed 54.06% in 2021, then decreased 24.29% in 2023.
  • Over 5 years, Invested Capital stood at $1.2 billion in 2021, then decreased by 24.08% to $907.3 million in 2022, then rose by 7.3% to $973.6 million in 2023, then grew by 11.25% to $1.1 billion in 2024, then grew by 0.89% to $1.1 billion in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $1.1 billion, $1.1 billion, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.